US to Test Medicare and Medicaid Coverage for Weight-Loss Drugs
TL;DR
The Trump administration is considering a five-year pilot program to expand coverage of weight-loss drugs like Wegovy, Ozempic, Zepbound, and Mounjaro under Medicare and Medicaid, marking a significant policy shift that could improve access but raises concerns about long-term costs.
- US plans to test Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports Reuters
- Medicare, Medicaid plan to experiment with covering weight loss drugs The Washington Post
- Trump officials plan coverage for weight loss drugs under Medicare and Medicaid The Guardian
- Medicare, Medicaid to try coverage of GLP-1s for obesity, report says Axios
- Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem. Barron's
Want the full story? Read the original reporting
Read on Reuters